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The discovery that somatic cells can be reprogrammed to pluripo-
tent stem cells (induced pluripotent stem cells, iPSC; Takahashi &
Yamanaka, 2006), capable of differentiating to all cell types present in
the adult organism, and especially the rapid adaptation of the technolo-
gy to human cells (Takahashi et al., 2007; Yu et al., 2007) has generated
large expectations concerning the possible applications. The technology
has a particularly strong appeal for disciplines such as cardiovascular
medicine, which deal with cell types (e.g., cardiomyocytes) that cannot
be easily obtained from human probands or patients. Among theechnische UniversitätMünchen,
22, 81675 Munich, Germany.
-NC-ND license.possible applications of iPSC technology in the cardiovascular ﬁeld, the
potential usefulness in drug development as well as in drug toxicity
testing has been already highlighted in the initial reports on the gener-
ation of human iPSC (Takahashi et al., 2007; Yu et al., 2007). The aim of
this review is to deﬁne the possible role of iPSC-derived cardiomyocytes
in this context, to point out the achievements that have been already
made in this regard, and to discuss the crucial steps that have to be
taken before this technology can be broadly used in drug development
and toxicity testing.2. Possible applications of induced pluripotent stem cell-derived
cardiomyocytes in drug development and toxicity testing
The identiﬁcation and characterization of potential drug targets, the
screening of compound libraries for drugs with a desired effect, as well
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all require reliable test systems. Such test systems can be
engineered based on primary cells, immortalized cell lines, or ani-
mal models; however, cardiovascular pharmacology suffers from
several drawbacks of the currently-used test systems based on
cardiomyocytes.
Primary human cardiomyocytes are not easily obtained and cannot
be kept in culture for prolonged time periods or expanded in vitro. Im-
mortalized human cardiomyocyte cell lines that faithfullymodel impor-
tant aspects of cardiac physiology such as action potentials are not
available. Alternatively, human cell cultures derived from embryonic
sources, such as human embryonic kidney (HEK) lines, can be used to
generate overexpression systems of the potential drug target molecule
(Goineau et al., 2012). This allows studying the effects of a drug on a
speciﬁc gene or molecular mechanism, but fails to provide information
on the compound's overall cellular (cardiomyocyte) outcome. Thus,
currently, much of the research in this ﬁeld depends on animal models.
For example, genetically-modiﬁedmice are frequently used to study the
physiology that underlies humanheart disease. However, species differ-
ences are a relevant problem if cardiomyocytes from laboratory animals
are used to model features of human cardiovascular disorders. For ex-
ample, murine hearts beat about 6–10 times faster than their human
counterparts, with markedly shorter action potentials that are shaped
by different ion channels. In humans, mutations of the KCNQ1 gene
encoding the ion channel responsible for the IKs current may cause the
long-QT syndrome type 1, a disease characterized by a prolonged QT in-
terval in the ECG and a susceptibility to potentially lethal arrhythmias
(Lehnart et al., 2007). However, genetic ablation of KCNQ1 in mice did
not consistently lead to a cardiac phenotype in accordance with that
of long-QT syndrome patients (Lee et al., 2000; Casimiro et al., 2001).Fig. 1. Possible applications of induced pluripotent stem cells in drug development and toxicitThemost likely cause for these discrepancies is the fact that the repolar-
ization of the cardiac action potential is governed by different ionic cur-
rents in mice and men (e.g., the main repolarizing currents are the
delayed rectiﬁer currents IKr and IKs in human, but other currents, like
the transient outward potassium current Ito, play critical roles in the re-
polarization phase of mouse ventricular myocardium) (Kaese &
Verheule, 2010; Nerbonne et al., 2001). These species differences are
not only relevant for themodeling of a rare disorder, such as congenital
long-QT syndrome, but also call into question the validity of rodent
models to predict drug-induced QT interval prolongation, a major
issue in drug development due to its potentially detrimental effects.
Taken together, there is a yet unmet need for better model systems of
human heart disease. Induced pluripotent stem cells (iPSC) bear the po-
tential to ﬁll this gap by providing an unlimited source of both healthy
and diseased human cardiomyocytes (Fig. 1). Speciﬁcally, there are at
least three areas inwhich iPSC-derived cardiomyocytesmightmake im-
portant contributions to the ﬁeld of pharmacology and toxicology. One
area is the identiﬁcation of novel drug targets. Patient-speciﬁc iPSC
lines generated from patients with genetically-caused diseases can be
used as a source of patient-speciﬁc cardiomyocytes. In vitro studies
with these cardiomyocytesmight lead to the identiﬁcation ofmolecules
involved in the pathophysiology of the diseases that represent possible
novel drug targets. A second area inwhich iPSC-derived cardiomyocytes
might advance pharmacology is the use of these cells in phenotypic as-
says to screen compound libraries for beneﬁcial cardiovascular effects.
The third area is safety pharmacology. It is crucial to screen candidate
drugs for cardiotoxicity, particularly for (but not limited to) their poten-
tial to prolong the QT interval and to induce torsades de pointes. Pheno-
typic assays based on iPSC-derived cardiomyocytes hold a great promise
to complement or to replace currently-used assays based either ony testing, and important considerations that have to be made in the planning of such use.
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expressing ion channels.
3. Generation of induced pluripotent stem cellerived
cardiomyocytes — considerations on reprogramming and
differentiation protocols
3.1. Reprogramming
The ﬁrst reportedmethod for the generation of iPSC used integrating
retroviruses to deliver four transcription factors (Oct3/4, Sox2, c-Myc
and Klf-4) to ﬁbroblasts (Takahashi & Yamanaka, 2006). Since then,
rapid progress has been made in reprogramming various somatic cell
types usingmany variants of the original cocktail of reprogramming fac-
tors, including chromatin-modifying small molecules. Moreover, nu-
merous methods for delivering the reprogramming factors to the cells,
such as non-integrating genomic approaches (Gonzalez et al., 2011)
have been applied. Consequently, it is now possible to use easily acces-
sible somatic cells from a patient (e.g., skin ﬁbroblasts, hair follicles, or
whole blood) to generate iPSC lines that are free from viral transgenes
and genetically identical to the patient (Jia et al., 2010; Seki et al.,
2010; Yakubov et al., 2010; Narsinh et al., 2011).
3.2. Differentiation
To use iPSC-derived cardiomyocytes for drug development or safety
pharmacology, the availability of reliable protocols to differentiate iPSC
to cardiomyocytes is crucial. The major aim of cardiac differentiation
protocols is to provide the differentiating cells with the speciﬁc cues
necessary to direct their development towards a cardiomyocytic fate.
Therefore, it is important to understand the regulation of cardiac differ-
entiation, an area in which substantial progress has been made during
the past decade (Laﬂamme et al., 2007; Yang et al., 2008; Kattman
et al., 2011; Burridge et al., 2012). Differentiation of iPSC to cardiovascu-
lar cells is a multistep process tightly regulated by developmental sig-
nals, epigenetic programs and extracellular microenvironments
(reviewed in Moretti et al., 2013). This process involves diverse path-
ways such as BMP, TGF-b/activin/nodal,WNT/b-catenin, and FGF signal-
ing. Developments in order to more efﬁciently direct the developing
cells towards the cardiomyocyte lineage include co-culture with END-
2 stromal cells (Mummery et al., 2003) and ascorbic acid, which en-
hances collagen synthesis and promotes proliferation of cardiac progen-
itors (Cao et al., 2012). Microenvironmental factors that are potentially
important for cardiac differentiation are not limited to paracrine factors,
but may also include other factors present during embryonic heart de-
velopment, such as mechanical stretch and rhythmic electric activity.
Consequently, biomatrices with deﬁned elastic properties (Engler
et al., 2008) and electrical stimulation (Nunes et al., 2013) have been ap-
plied to promote cardiac differentiation of pluripotent stem cell-derived
cardiomyocytes.
3.3. Maturity of induced pluripotent stem cell-derived cardiomyocytes
A key problem so far unresolved is posed by the fact that
cardiomyocytes generated frompluripotent stemcellswith the current-
ly available protocols are immature compared to their adult counter-
parts. In many aspects, the cells are more similar to fetal than to adult
cardiomyocytes. Morphologically, the cells lack a fully-developed trans-
verse tubule system (Lieu et al., 2009). Functionally, the cells are fre-
quently characterized by spontaneous contractions, which are not
found in adult ventricular cardiomyocytes. The maximum diastolic
membrane potential is less negative than that in adult cardiomyocytes,
and the action potential upstroke velocities and amplitudes are similar
to those of the 10-week-old embryonic hearts (Mummery et al.,
2003). Conﬂicting data exist regarding thematurity of the calcium han-
dling system in pluripotent stem cell-derived cardiomyocytes, althoughthere is evidence that at least basic components of the calcium cycling
machinery and excitation–contraction coupling are functional (Satin
et al., 2008; Itzhaki et al., 2011b; Jung et al., 2012; Novak et al., 2012).
The transcriptional proﬁles of iPSC-derived cardiomyocytes are also
similar to those of fetal cardiomyocytes (Gupta et al., 2010).
3.4. Heterogeneity of induced pluripotent stem cell-derived cardiomyocytes
The cardiomyocytes generated by current differentiation protocols
are a mixture of cells belonging to all three major cardiomyocyte sub-
types: cells with atrial-, ventricular- and nodal-like phenotypes. While
this can be considered an advantage due to the possibility to assess
physiological properties in all these cell types, it also holds thedisadvan-
tage that changes that occur only in one subpopulation of cells may be
diluted if the readout is taken from all cells. Particularly, this problem
is likely to arise in assays that do not record the action potential of single
cells, which is the most straightforward method to classify each cell as
atrial-, ventricular- or nodal-like. It is thus important to understand
the mechanisms of cardiac subtype speciﬁcation, and signiﬁcant efforts
have been made to develop protocols that reduce heterogeneity of
human pluripotent stem cell-derived cardiomyocytes. For example, in-
hibition of NRG-1b/ERBB signaling has been shown to enhance the pro-
portion of nodal-like cells (Zhu et al., 2010), and retinoid signals
enhance atrial versus ventricular speciﬁcation during cardiac hESC dif-
ferentiation (Zhang et al., 2011).
3.5. Puriﬁcation of induced pluripotent stem cell-derived cardiomyocytes
Especially for high-throughput applications, it is essential to be able
to generate populations of iPSC-derived cardiomyocytes or even cardio-
myocyte subtypes of a high purity. Consequently, many research efforts
have been undertaken in order to reach this goal. The identiﬁcation of
markers expressed speciﬁcally on cardiomyocytes, including EMILIN2
(Van Hoof et al., 2010), SIRPA (Dubois et al., 2011; Elliott et al., 2011)
and VCAM (Elliott et al., 2011; Uosaki et al., 2011) has made it possible
to isolate highly enriched populations of these cells from pluripotent
stem cells by FACS or magnetic bead sorting. However, speciﬁc surface
markers for iPSC-derived cardiomyocyte subtypes (ventricular-, atrial-
and nodal-like cells) have not yet been discovered. Meanwhile, the
introduction of ectopic reporters or the targeting of endogenous loci is
becoming a very useful tool for cell-type-speciﬁc lineage marking.
Selectable markers, such as ﬂuorescent markers or antibiotic resistance
genes, under the control of lineage-speciﬁc promoters allow for
puriﬁcation of precise cell populations by either FACS or selection
with antibiotics. Using this approach, the human α-myosin heavy-
chain (α-MHC) promoter coupled to a bicistronic reporter (GFP and pu-
romycin) has been used to achieve high purity of cardiomyocytes (90%)
from differentiating human embryonic stem cells (Anderson et al.,
2007). Ventricular-like cardiomyocytes can be marked by lentiviral de-
livery of a selectable human myosin light chain-2v (MLC2v) enhancer
driving EGFP expression (Huber et al., 2007). Generation of reporters
for the other cardiomyocyte subtypes has been so far hampered by
the fact that, in contrast to adult cardiomyocytes, iPSC-derived cardio-
myocyte subtypes are not explicitly characterized by subtype-speciﬁc
expression of proteins, such as the atrial isoform of MLC2 (MLC2a) for
atrial or the hyperpolarization-activated cyclic nucleotide-gated potas-
sium channel 4 (HCN4) for conduction system cells.
4. Pharmacology of induced pluripotent stem cell-derived
cardiomyocytes — lessons from disease modeling studies
Soon after the initial description of human iPSC, the ﬁrst studies
aimed at modeling cardiac diseases with patient-speciﬁc stem cells
have been published. A summary of these disease modeling studies is
provided in Table 1. The ﬁrst diseases that have been investigated
using this approach weremonogenic channelopathies, such as different
Table 1
Modeling heart disease with patient-speciﬁc iPSC.
Disease Reference Genetic basis Tested drugs
Long-QT syndrome
LQT1 Moretti et al., 2010 KCNQ1 c.569GNA; p.R190Q Propranolol, isoprenaline
Egashira et al., 2012 KCNQ1 c.1893delC; p.P631fs/33
LQT2 Itzhaki et al., 2011a KCNH2 c.1841CNT; p.A614V Nifedipine, pinacidil, ranolazine
Matsa et al., 2011 KCNH2 c.1681GNA; p.A561T Propranolol, isoprenaline, nicorandil, PD-118057,
Matsa et al., 2013 KCNH2 c.1681GNA; p.A561T Allele-speciﬁc siRNA
Lahti et al., 2012 KCNH2 c.526CNT; p.R176W Erythromycin, sotalol, cisapride
LQT3, Brugada Syndrome Davis et al., 2012 SCN5A c.5387_5389ins TGA; p.1795insD
LQT8, Timothy Syndrome Yazawa et al., 2011 CACNA1C c.1216GNA; p.G406R Roscovitine
Catecholaminergic polymorphic ventricular tachycardia
CPVT1 Fatima et al., 2011 RYR2 c.7447TNA; p.F2483I Isoprenaline, forskolin
Jung et al., 2012 RYR2 c.1217CNT; p.S406L Dantrolene
Itzhaki et al., 2012 RYR2 c.12056TNG; p.M4109R Flecainide, thapsigargin
CPVT2 Novak et al., 2012 CASQ2 c.1183GNC; p.D307H
Cardiomyopathies
DCM Sun et al., 2012 TNTT2 p.R173W Metoprolol, norepinephrine
HCM Lan et al., 2013 MYH7 c.1988GNA; p.R663H Propranolol, verapamil, nifedipin, diltiazem, lidocaine,
mexiletine, ranolazine
LEOPARD syndrome Carvajal-Vergara et al., 2010 PTPN11 c.140CNT; p.T468M
ARVC Ma et al., 2013 PKP2 c.1841TNC; p.L614P Nifedipine, isoprenaline
Kim et al., 2013 PKP2 c.2484CNT; r2483_2489del c.2013delC; p.R672fsX683
Caspi et al., 2013 PKP2 c.972InsT/N; p.A324fs335X PKP2 c.148_151delACAG/N;
p.T50SfsX110
Isoproterenol, carbamylcholine, BIO
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tricular tachycardia (CPVT). The cell-autonomous pathophysiology of
these disorders allows the investigation of disease-speciﬁc phenotypes
in single cells. Accordingly, single-cell methodologies such as patch
clamp electrophysiology, ﬂuorometric calcium imaging using calcium-
sensitive dyes and single cell RT-PCR were used in these studies. Most
of these studies have already investigated the effect of drugs on
the patient-speciﬁc iPSC-derived cardiomyocytes (Table 1). Drugs al-
ready known to have an effect on the disease phenotype in patients
(e.g., beta blockers in long-QT syndrome) were used, mainly to demon-
strate that the in vitro disease models recapitulate key features of the
disease. However, in some studies, novel pharmacological concepts
have been evaluated. For example, it was shown that dantrolene, a
drug clinically used for the treatment of malignant hyperthermia, was
able to revert the arrhythmogenic phenotype in cardiomyocytes affect-
ed by CPVT caused by a mutation of the cardiac ryanodine receptor cal-
cium channel (Jung et al., 2012).
Patient-speciﬁc iPSC-derived cardiomyocytes have been even used
to investigate a novel RNA-based treatment strategy for long-QT syn-
drome (Matsa et al., 2013; Sinnecker et al., 2013). In cardiomyocytes af-
fected by long-QT syndrome type 2 caused by an A516Tmutation in the
KCNH2 gene encoding the hERG potassium channel, it was shown that
the mutation exerted a dominant-negative effect on the hERG-
mediated IKr current: A hERG potassium channel is formed by four
KCNH2 subunits. In patient cardiomyocytes, which are heterozygous
for the A516T mutation, wild type and mutated KCNH2 subunits are
presumably synthetized in equal amounts. The mutated subunits are
able to co-assemble withwild type subunits, but the resulting ion chan-
nel tetramers are not correctly incorporated into the plasmamembrane
if they contain one or more mutated subunits. Consequently, in patient
cardiomyocytes, the IKr current is reduced not only to 50% (whichwould
indicate a haploinsufﬁciency mechanism of the mutation), but to less
than 10%, leading to a marked prolongation of the action potential. Tak-
ing advantage of this dominant-negativemechanism, the authors of the
study designed an allele-speciﬁc small interfering RNA that speciﬁcally
led to a knockdown of the mutated, but not of the wild type KCNH2
mRNA. This strategy reduced the amount of mutated KCNH2 subunits
interfering with membrane trafﬁcking of the wild type subunits,increasing the IKr level and thereby signiﬁcantly reducing the action po-
tential duration.4.1. Choice of control lines
An important consideration that has to be made in the planning of
such disease modeling studies is the choice of the experimental control.
In many of the early studies (e.g., Moretti et al., 2010; Itzhaki et al.
2011a; Fatima et al., 2011; Yazawa et al., 2011), control cells were
cardiomyocytes generated from iPSC lines obtained from unrelated
healthy donors. While this approach is straightforward, it bears the
risk that phenotypic differences between patient and control cells do
not arise from the disease-causing mutation, but by differences in the
genetic background. This problem becomes especially relevant when
diseases are studied in which the suspected phenotypic effect of the
disease-causing mutation is weak, or in which the suspected effect of
the genetic background is strong (e.g., diseases known for incomplete
penetrance). Also in cases in which the evidence for the causation of a
phenotype by a speciﬁc mutation is weak (e.g., in cases of newly-
identiﬁedmutations in genes not implicated before in a speciﬁc pathol-
ogy), it is important to rule out genetic background variability as the
cause of the phenotype observed in iPSC-derived cardiomyocytes.
To reduce the genetic background variability between patient and
control cells, iPSC lines generated from family members of the patient
unaffected by the disease have been used (Carvajal-Vergara et al.,
2010; Sun et al., 2012; Lan et al., 2013). However, it should be noted
that this approach can only limit, but not abolish the genetic back-
ground variability, given that even siblings or parent–child pairs only
have 50% genetic overlap.
A promising approach to control background variability is to genet-
ically modify pluripotent cell lines by means of gene targeting (Bellin
et al., 2013) to generate pairs of isogenic lines that genetically differ
only in themutation of interest. Such amodiﬁcation can consist of either
correcting the disease-causingmutation in a patient-derived cell line or,
as a complementary approach, of engineering a known disease-causing
mutation into a cell line derived from a healthy person. With this ap-
proach, even subtle differences in action potential duration between
250 D. Sinnecker et al. / Pharmacology & Therapeutics 143 (2014) 246–252healthy and diseased cells could be reliably measured and unequivocal-
ly attributed to a KCNH2mutation (Bellin et al., 2013).
5. Exploiting the potential of induced pluripotent stem cell-derived
cardiomyocytes for pharmacological and
toxicological screening — phenotype-based assays
In contrast to other systems frequently used in drug development,
such as cell lines overexpressing speciﬁc ion channels, iPSC-derived
cardiomyocytes bear the potential to be used in phenotype-based as-
says. In such assays, the readout is not drug effect on a known target
structure (e.g., the currentmediated by a speciﬁc ion channel), but rath-
er a complex phenotype, such as the beating rate, action potential dura-
tion, or the occurrence of arrhythmias. An important advantage of such
phenotypic assays is that it is possible to evaluate the effect of drugs that
do not interact with known target molecules. For example, the cardiac
action potential is shaped by the complex gating behavior of more
than a handful of ion channels, many of which are composed of several
subunits encoded by different genes. While the effects of a compound
on a single ion channel gating can be studied in immortalized cell
lines, such assays may not always answer the question which effect
the compound will have on a cardiomyocyte. Many drugs that prolong
the QT interval do so by inhibiting hERG activity, which can be assessed
using hERG-overexpressing cell lines; other drugs (e.g., alfuzosin
(Lacerda et al., 2008)) do so by a different mechanism of action. The
QT-prolonging (and thus hazardous) potential of these drugs is there-
fore likely to be overlooked if relying solely on a hERG assay. On the
other hand, there are drugs, such as verapamil, that block hERG in
doses near to therapeutic plasma concentrations (Redfern et al.,
2003), but do not prolong the QT interval in patients (Nademanee &
Singh, 1988). Thus, similarly-behaving novel compounds might not
enter the clinic nowadays due to being sorted out early in the drug de-
velopment process due to their action on hERG.
Assays that measure the action potential duration in iPSC-derived
cardiomyocytes might provide a solution to these two problems. This
has been demonstrated by measuring action potential durations in the
whole cell patch clamp conﬁguration in iPSC-derived cardiomyocytes
(Liang et al., 2013): Alfuzosin, but not verapamil signiﬁcantly prolonged
action potential duration in therapeutic concentrations, in contrast to
the effects on hERG elicited by the two drugs. These observations
could be also reproduced in an assay that used microelectrode arrays
(MEA) tomeasure the ﬁeld potential duration,which is closely correlat-
ed to the action potential duration of single cardiomyocytes (Navarrete
et al., 2013). The use ofMEA instead of single-cell patch clampmeasure-
ments is an important step towards increasing the throughput of such
assays.
To bring the potential of iPSC-derived cardiomyocytes for pharma-
cological and toxicological screening to fruition, the incorporation of
these cells into reliable assays that can be scaled up to medium- or
high-throughput applications would be desirable. Several attempts to
reach this goal have been already made. Drug-induced cardiotoxicity
can manifest as cardiomyocyte cell death. Using high-content automat-
ed microscopy in a 96-well format in conjunction with live cell staining
as well as immunoﬂuorescence, the effect of drugs on a panel of cell
death-related abnormalities, such as nuclear shape change and frag-
mentation, DNA degradation, caspase activation, mitochondrial outer
membrane permeabilization, and cell detachment was assessed in
iPSC-derived cardiomyocytes (Mioulane et al., 2012). This approach
bears the possibility to obtain speciﬁc cardio-toxicity proﬁles of drug
candidates in vitro, which might be then compared to those of sub-
stances with proven cardiotoxic potential, such as doxorubicin.
Another step towards high-throughput application of iPSC-derived
cardiomyocytes is an assay thatmeasures the beating rate based on cal-
cium transients imagedwith ﬂuorescent indicators, which has been im-
plemented in a 96- and 384-well format (Sirenko et al., 2013). By
applying drugs in different concentrations using automated liquidhandling, dose–response curves for several drugs that affect the beating
rate could be recorded with good reproducibility. Moreover, the assay
also allows for the analysis of arrhythmias based on morphological
changes of the calcium transients such as prolongations that were
found with some drugs known to prolong the QT interval. However, it
has not been systematically investigated whether such alterations in-
deed correlate with established measures of arrhythmogenesis, such
as action potential prolongation, early afterdepolarizations, or triggered
activity.
A phenotypic assay for drugs interfering with cardiac hypertrophy
has been also adapted for use in a 384-well format (Carlson et al.,
2013). Treatment of human iPSC-derived cardiomyocytes with
endothelin-1 reproducibly led to actin remodeling, an increase in cell
size and increased expression of brain natriuretic peptide (BNP). The
endothelin-induced increase in intracellular BNPwas imaged by immu-
noﬂuorescence using automated microscopy and image analysis. This
technology allowed the investigation of the dose-dependent effect of
several drugs on this surrogate parameter for the cardiac hypertrophic
response.
6. Critical prospect
It is widely recognized that iPSC-derived cardiomyocytes have a
huge potential to advance drug development and toxicity testing. How-
ever, in order to fulﬁll this potential, several important issues will have
to be resolved. Standardization of methods for iPSC generation, cardiac
differentiation and quality control will be necessary if these cells are
to be incorporated into standardized assays. The commercial availability
of well-characterized iPSC-derived cardiomyocytes (Ma et al., 2011)
might represent one important step towards this goal. The advance-
ment of differentiation protocols in order to generate cells that are
more similar to adult cardiomyocytes is another important step. De-
pending on the planned application, the immature phenotype of
cardiomyocytes generated with current protocols might represent a
more or less relevant problem. The most important question that has
to be answered for each proposed assay is to which extent the pheno-
type observed in iPSC-derived cardiomyocytes treated with a speciﬁc
drug correlates with the clinical ﬁndings in patients treated with the
same drug. This will have to be systematically investigated – by testing
asmany drugs as possible – before the usefulness of the assay can be re-
liably predicted.
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